| 1.77 -0.07 (-3.8%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.05 |
1-year : | 3.78 |
| Resists | First : | 2.61 |
Second : | 3.24 |
| Pivot price | 1.95 |
|||
| Supports | First : | 1.6 | Second : | 1.33 |
| MAs | MA(5) : | 1.76 |
MA(20) : | 1.95 |
| MA(100) : | 4.3 |
MA(250) : | 3.6  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 11.8 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 145.46 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PPCB ] has closed above bottom band by 25.7%. Bollinger Bands are 84.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.75 - 1.76 | 1.76 - 1.77 |
| Close: | 1.75 - 1.77 | 1.77 - 1.79 |
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Thu, 02 Oct 2025
Does Propanc Biopharma (NASDAQ:PPCB) Have A Healthy Balance Sheet? - simplywall.st
Mon, 29 Sep 2025
Propanc Biopharma, Inc. SEC 10-K Report - TradingView
Wed, 17 Sep 2025
Propanc Biopharma Receives Certificate of Grant for - GlobeNewswire
Wed, 20 Aug 2025
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Tue, 19 Aug 2025
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Tue, 19 Aug 2025
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.281e+007 (%) |
| Held by Institutions | 6.48e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.728e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -363.4 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.61 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -14.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.2 |
| Price to Cash Flow | 56.04 |
| Dividend | 188410 |
| Forward Dividend | 812 |
| Dividend Yield | 10644600% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|